Go to AAD Home
Donate For Public and Patients Store Search

Go to AAD Home
Welcome!
Advertisement
Advertisement

2022: Best of DermWorld Insights and Inquiries


DII small banner

December 29, 2022

We know how much you enjoy Dr. Heymann and the editorial board’s weekly analyses of dermatologic literature, so we’ve created a list of the top 10 most popular issues in 2022 — starting with the most popular issue of the year.

1. Coming full circle (almost) — Low dose oral minoxidil for alopecia

I presume that virtually every dermatologist reading this commentary has recommended topical minoxidil for their patients with androgenetic alopecia and other alopecias (telogen effluvium, alopecia areata, hair shaft abnormalities, and eyebrow hypotrichosis). Keep reading.

2. Eye-opening news about oxymetazoline

Certain articles have a “wow” factor that immediately impacts practice. In 2007, I recall being impressed by the 2 cases of erythematotelangiectatic rosacea reported by Shanler and Ondo that dramatically improved with the application of oxymetazoline hydrochloride 0.05%. Keep reading.

3. An old dog with a new trick — High dose intralesional steroids in hidradenitis suppurativa

Hidradenitis suppurativa (HS) is hitting its stride academically — deservedly so. In 2000 there were two publications about HS in JAAD; in 2010, nine manuscripts; and, in 2020, 69 articles were published. Keep reading.

4. The globalization of monkeypox

Here we go again. I have not thought much about monkeypox (MP) since 2003 when a documented case appeared in a 3-year-old girl from central Wisconsin. Keep reading.

5. Probing pityriasis rosea in pregnancy

I have always been captivated by pityriasis rosea (PR). As a second-year medical student, my late brother Andrew (presumably) developed it. I was clueless when he showed me his rash. Keep reading.

6. Tag, you’re it!

Chances are you will see a patient with skin tags today. Patients will likely ask you two questions: Why do I get them? What do you mean my insurance won’t cover their removal (for asymptomatic lesions)? Keep reading.

7. The ever-changing world of nevus sebaceus

The aphorism in medical education that half of what you learn in medical school will prove to be wrong could use the nevus sebaceus (sebaceous) of Jadassohn as its poster child. Keep reading.

8. Lightening the cutaneous and emotional burden of melasma — cysteamine’s role

Melasma is a frustrating disorder for patients and practitioners alike. Facial gray-brown patches may cause psychosocial distress and embarrassment, thereby diminishing quality of life. Keep reading.

9. JAKne is on the horizon

If you are like me, you have read much more about JAK inhibitors (JAKi) than have prescribed them. We are all on a learning curve. Keep reading.

10. Isotretinoin and diabetes: Of familiarity and surprise

Since 1982 I have been married to my wife and isotretinoin. Before its availability, only limited options were available for treating severely inflammatory acne. I am astounded that after approximately 15,000 days there is something new to learn about each. Keep reading.

To view all issues of DermWorld Insights and Inquiries published this year, browse the 2022 archive.


All content found on Dermatology World Insights and Inquiries, including: text, images, video, audio, or other formats, were created for informational purposes only. The content represents the opinions of the authors and should not be interpreted as the official AAD position on any topic addressed. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

DW Insights and Inquiries archive

Explore hundreds of Dermatology World Insights and Inquiries articles by clinical area, specific condition, or medical journal source.

Access archive

All content solely developed by the American Academy of Dermatology

The American Academy of Dermatology gratefully acknowledges the support from Bristol Myers Squibb.

Bristol Myers Squibb Logo

Advertisement
Advertisement